NASDAQ · Biotechnology

DNLI (DNLI) Stock

$24.42 +1.03% NASDAQ: DNLI Healthcare

Valuation

MetricValue
Price$24.42
Market Cap$3.88B
P/E Ratio-6.20
P/B Ratio2.88
P/S Ratio0.00
EPS (TTM)$-2.97
52-Week High$27.21
52-Week Low$12.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.59%
ROA-44.80%
ROCE-54.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio9.19

Annual Financials (USD)

Metric20212022202320242025
Revenue$49.0M$108.0M$331.0M$0$0
Operating Profit$-296.0M$-341.0M$-197.0M$-487.0M$-555.0M
Net Profit$-291.0M$-326.0M$-145.0M$-423.0M$-513.0M
EPS$-2.39$-2.60$-1.06$-2.57$-2.97
Op Margin-607.8%-314.2%-59.5%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.4B$1.5B$1.2B$1.4B$1.1B
Total Liabilities$442.0M$418.0M$123.0M$144.0M$131.0M
Cash$293.0M$218.0M$127.0M$175.0M$205.0M
Borrowings$64.0M$60.0M$52.0M$49.0M$42.0M

Latest News

Will Recent Setbacks Impact Growth Prospects of DNLI Stock? Zacks · Jul 15, 2026 Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights Exec Edge · Jul 15, 2026 Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating MT Newswires · Jul 13, 2026 Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s? Barrons.com · Jul 13, 2026 Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-211.0M$-245.0M$-358.0M$-348.0M$-413.0M
Investing Cash Flow$-30.0M$-159.0M$236.0M$-105.0M$246.0M
Financing Cash Flow$19.0M$14.0M$0$17.0M$0
Net Cash Flow$-214.0M$-75.0M$-91.0M$48.0M$32.0M
Free Cash Flow$-220.0M$-263.0M$-371.0M$-364.0M$-422.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-14.36%
Quick Ratio9.28
Interest Coverage—
Return 1Y70.73%
Return 3Y-18.74%
Return 5Y-62.94%

Ownership

Insiders Held9.16%
Institutions Held105.04%
Institutions Float Held115.63%
Institutional HolderSharesReport Date
Blackrock Inc.13,034,4342026-03-31
BAILLIE GIFFORD & CO12,066,4792026-03-31
T. Rowe Price Investment Management, Inc.8,519,1922026-03-31
Temasek Holdings (Private) Ltd7,012,9742026-03-31
State Street Corporation6,272,0012026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
COGT $42.27 -1.33% -34.70 $7.22B 0.00%
ETNB89bio, Inc. $14.84 +0.00% -12.82 $2.20B 0.00%
GLPGGalapagos N.V. $27.98 +1.71% 3.57 $1.84B 0.00%

About DNLI

DNLI stock trades at $24.42 with a market capitalization of $3.88B. The stock is valued at a price-to-earnings (P/E) ratio of -6.20, price-to-book of 2.88, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.58 and $27.21, and currently trades 10.3% below its 52-week high.

On profitability, DNLI generates a return on equity (ROE) of -50.59%, return on capital employed of -54.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides